Moleculin Biotech
MBRX
6 hedge funds and large institutions have $213K invested in Moleculin Biotech in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
20% more funds holding
Funds holding: 5 → 6 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
16% less capital invested
Capital invested by funds: $254K → $213K (-$41K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$73.7K |
| 2 |
Truist Financial
Charlotte,
North Carolina
|
+$60.3K |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$53.6K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.6K |
| 5 |
Citigroup
New York
|
+$6.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IG
ING Group
Amsterdam,
Netherlands
|
-$122K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$66K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Bank of America
Charlotte,
North Carolina
| $57K | +$73.7K | +11 | New |
|
|
2
Truist Financial
Charlotte,
North Carolina
| $46K | +$60.3K | +9 | New |
|
|
BFA
3
BlackRock Fund Advisors
San Francisco,
California
| $41K | +$53.6K | +8 | New |
|
|
4
Vanguard Group
Malvern,
Pennsylvania
| $41K | +$53.6K | +8 | New |
|
|
5
Citigroup
New York
| $17K | +$6.7K | +1 | +50% |
|
6
UBS Group
Zurich,
Switzerland
| $5K | – | – | – |
|
|
AWMS
7
Advocacy Wealth Management Services
Atlanta,
Georgia
| $2K | – | – | – |
|
8
Morgan Stanley
New York
| $2K | – | – | – |
|
|
NFG
9
Next Financial Group
Houston,
Texas
| $1K | – | – | – |
|
|
WA
10
WFG Advisors
Dallas,
Texas
| $1K | – | – | – |
|
|
IG
11
ING Group
Amsterdam,
Netherlands
| – | -$122K | -9 | Closed |
|
|
VKH
12
Virtu KCG Holdings
New York
| – | -$66K | -5 | Closed |
|
|
AIM
13
Acrospire Investment Management
Chicago,
Illinois
| – | -$9K | -1 | Closed |
|
MBRX Hedge Fund Activity: Q4 2016 in Review
6 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q4 2016, worth a combined $213K — down 16% from $254K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MBRX positions and 3 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Bank of America, opening a new position worth an estimated $73.7K. The largest seller was ING Group, exiting entirely with an estimated $122K sold.
- 6 institutional investors held Moleculin Biotech (MBRX) as of Q4 2016, up from 5 in Q3 2016.
- Funds reported $213K of Moleculin Biotech stock for Q4 2016, down 16% quarter-over-quarter.
- 4 funds opened new Moleculin Biotech positions in Q4 2016 and 3 closed out, a net change of +1 holder.
- The largest Moleculin Biotech buyer in Q4 2016 was Bank of America, an estimated $73.7K added.
- The largest Moleculin Biotech seller in Q4 2016 was ING Group, an estimated $122K sold.
Based on aggregated 13F filings for Q4 2016.